Compare, Analyse Fresenius Kabi Onco. with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ACTAVIS (US) - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   ACTAVIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ACTAVIS
Dec-18
FRESENIUS KABI ONCO./
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs17614,478-   
Low Rs799,712-   
Sales per share (Unadj.) Rs37.73,551.4-  
Earnings per share (Unadj.) Rs5.1-1,143.9-  
Cash flow per share (Unadj.) Rs6.7374.2-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.514,647.7-  
Shares outstanding (eoy) m158.23332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 99.1%   
Avg P/E ratio x25.0-10.6 -236.3%  
P/CF ratio (eoy) x18.932.3 58.6%  
Price / Book Value ratio x3.00.8 362.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1354,022,682 0.5%   
No. of employees `0001.216.9 6.8%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.269,892.5 7.4%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.6-22,512.4 -3.1%   
INCOME DATA
Net Sales Rs m5,9631,181,183 0.5%  
Other income Rs m1822,588 0.1%   
Total revenues Rs m5,9811,203,771 0.5%   
Gross profit Rs m1,43030,953 4.6%  
Depreciation Rs m258504,930 0.1%   
Interest Rs m-2668,161 -0.0%   
Profit before tax Rs m1,216-519,550 -0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68132,506 -0.1%   
Tax Rs m342-6,584 -5.2%   
Profit after tax Rs m806-380,460 -0.2%  
Gross profit margin %24.02.6 915.2%  
Effective tax rate %28.11.3 2,220.3%   
Net profit margin %13.5-32.2 -42.0%  
BALANCE SHEET DATA
Current assets Rs m5,102484,460 1.1%   
Current liabilities Rs m2,385428,569 0.6%   
Net working cap to sales %45.64.7 962.7%  
Current ratio x2.11.1 189.2%  
Inventory Days Days15020 766.1%  
Debtors Days Days11366 170.9%  
Net fixed assets Rs m5,148133,703 3.9%   
Share capital Rs m1580-   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,7324,871,829 0.1%   
Long term debt Rs m9521,715,548 0.1%   
Total assets Rs m10,3887,615,778 0.1%  
Interest coverage x-45.8-6.6 691.2%   
Debt to equity ratio x0.10.4 40.2%  
Sales to assets ratio x0.60.2 370.1%   
Return on assets %7.5-4.1 -183.1%  
Return on equity %12.0-7.8 -153.3%  
Return on capital %14.6-4.8 -301.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,274421,992 0.3%  
From Investments Rs m-1,204231,830 -0.5%  
From Financial Activity Rs m-196-724,265 0.0%  
Net Cashflow Rs m-126-70,091 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.82 Rs / USD

Compare FRESENIUS KABI ONCO. With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: FULFORD INDIA  BIOCON   WYETH  ELDER PHARMA  JUBILANT PHARMOVA   



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views On News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits (Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

FEATURED VIDEOS

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

More Featured Videos

MARKET STATS